INTRODUCTION
CD8 T cells specific for the HLA-A2-restricted peptides WT1 and PR1, which are derived from endogenous leukemia-associated antigens (LAAs) Wilms' tumor antigen, [1] [2] [3] and proteinase 3, respectively, mediate cytotoxicity against myeloid leukemia. PR1-specific T cells also contribute to cytogenetic remission of chronic myeloid leukemia (CML) in patients treated with interferon 4, 5 and vaccination with WT1 and PR1, 6, 7 can induce specific CD8 immunity in patients with myeloid malignancies. These results validate endogenous self-peptides as targets for immunotherapy, including vaccination, adoptive cell therapy, or antibodies that bind peptide/MHC. Such T cell receptor-like monoclonal antibodies (TCR-like mAbs) may have selective activity against leukemia if target peptide/MHC complexes are aberrantly expressed on leukemia. Furthermore, mAbs are easy to administer and can be dosed frequently, which may increase effectiveness against high leukemia burden. Eliciting TCR-like antibodies has been technically challenging, 8 primarily due to the high immunogenicity of HLA molecules in mice. Phage display libraries, 9 peptide/MHC immunization 10, 11 and the combination of both strategies 8, 12 have been used to produce TCR-like mAbs targeting peptides derived from solid tumor antigens (e.g. MAGE, β-HCG, TARP, NY-ESO-1) in the context of HLA-A1 or -A2. [9] [10] [11] 13, 14 Although antibody activity against primary tumors has not been well studied, complement dependent cytotoxicity (CDC) against tumor cell lines has been reported. 11 Some toxin-conjugated antibodies also show activity against tumor cells. 15, 14, 16 However, to eradicate cancer these antibodies should be active against cancer-initiating cells, and TCR-like mAbinduced cytolysis of cancer stem cells has not been reported. Nevertheless, because PR1-specific CTL suppress leukemia progenitor cells in vitro 17 and because CD34+CD38-Lin-cells are enriched for LSC 18 and can be easily studied, we hypothesized that if an anti-PR1/HLA-A2 antibody could be produced it may be active against blasts and LSC from HLA-A2+ AML patients. We report the discovery of 8F4, a novel mAb that binds with high affinity to a conformational epitope of PR1/HLA-A2 and induces dose-dependent cytolysis of myeloid leukemia but not normal hematopoietic cells. 8F4 mediates CDC against Lin-CD34+CD38-LSC and preferentially inhibits the growth of leukemia progenitor cells. These results justify further study of TCR-like antibodies to verify the differential effects against normal and leukemia stem cells. Biologically significant differences may justify further study of a humanized form of 8F4 as a novel treatment for leukemia.
MATERIALS AND METHODS
Patients and donors. Samples were collected after informed written consent was obtained in accordance with the Declaration of Helsinki under protocols approved by the University of Texas MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB). Cord blood (CB) were utilized from units that were rejected for clinical use due to low cell number. Mononuclear cells were separated by gradient density centrifugation, frozen and preserved in liquid nitrogen. 19 Cells were thawed, washed and recovered by overnight incubation in RPMI-1640 supplemented with 10% fetal bovine serum (complete media, CM) (Sigma, St. Louis, MO).
Generation of mouse anti-PR1/HLA-A2 monoclonal antibodies. PR1 (VLQELNVTV) was refolded with recombinant HLA-A2 and 2-microglobulin. Two 6 week-old mice were injected subcutaneously or intraperitoneally (IP) with a 300µL suspension comprised of 20µg purified PR1/HLA-A2 monomer mixed with either 12µg AbISCO-100 adjuvant (Isconova AB) 20 or Complete Freund Adjuvant (Fisher). The mice were immunized at 2-weeks intervals for a total of four times by IP injection of antigen plus adjuvant, followed by an IP injection of antigen alone 3 days prior to harvest of splenocytes. Three days prior to the final boost, serum was tested for polyclonal immune response by ELISA. Clones (n=950) were isolated by limiting dilution. After screening with parallel ELISA, selected clones were transferred to 24-well plates, and clones were grown in DMEM containing 4 mM L-glutamine, 20% fetal bovine serum (FBS) and 10% Hybridoma Cloning Factor (Fisher). Mice were purchased from Jackson Laboratories. Animal care and use was approved by MDACC Institutional Animal Care and Use Committee.
Cell cultures. T2 cells were purchased from ATCC and maintained in CM. For peptide loading, cells were washed twice and resuspended in RPMI-1640 at 10 6 cells/mL. After adding 20µl of PR1 (1-50µg) or control peptides, cells were incubated 4h at 37ºC, washed with PBS and used for flow cytometry or cellular assays.
ELISA and Surface Plasmon Resonance. HLA-A2-restricted peptides PR1, WT1 126 (RMFPNAPYL), cytomegalovirus-derived pp65 (NLVPMVATV), and influenza matrix protein-derived Flu (GILGFVFTL) were synthesized by MDACC facility to a minimum 95% purity. MHC-peptide monomers were synthesized as previously described.
21 PR1 analogs with alanine substitutions (ALA1-ALA9), minor histocompatibility antigen peptide HA-2 (YIGEVLVSV), and corresponding monomers were provided by M.G.D. Kester and Dr. J.H.F. Falkenburg (Leiden University Medical Center, Leiden, Netherlands). For hybridoma screening, 96 well Maxisorb Immunoplates (Nunc) were coated with recombinant streptavidin (1µg/mL, Sigma), blocked with blocking buffer (BB) containing 2% bovine serum albumin (BSA) in PBS and incubated with biotinylated complex peptide/HLA-A2 in BB. After washing, plates were incubated with supernatant or antibody for 1 hour at RT. Bound antibodies were detected by incubation with horseradish peroxidase-conjugated goat anti-mouse antibodies (1:4000, Jackson), following by TMB substrate (BD). Supernatant from BB7.2 hybridoma was used as a positive control. Parallel ELISA with PR1 and pp65 were used to increase the PR1 specificity of screening. Clones with > 50% higher signal with PR1/HLA-A2 compared to pp65/HLA-A2 were further investigated. For 8F4 specificity assays, plates were coated with control antigens and then processed as above.
Kinetics and affinities of the PR1/HLA-A2 binding to three antibodies (8F4, controls BB7.2 and anti-KLH IgG2a) was measured by surface plasmon resonance using BIAcore 3000 at the Center for Biomolecular Interaction Analysis (University of Utah). Binding studies were performed at 25ºC using a running buffer containing PBS, 0.005% Tween-20 and 0.1mg/mL BSA (pH7.4). Antibodies were captured on anti-mouse surfaces at densities of 95-240 RU. The PR1/HLA-A2 analyte was diluted to 100nM and tested in duplicate in a three-fold dilution series for binding to the antibody surfaces.
Flow cytometry and confocal imaging. 8F4 mAb was affinity purified from hybridoma supernatant using protein A sepharose and conjugated to the fluorochromes AlexaFluor-488, -647 and Phycoerythrin (PE) (Invitrogen). Cells were co-stained with 8F4 and anti-HLA-A2 mAb BB7.2 to confirm co-localization. Flow cytometry data was collected with FACSCantoII (Becton Dickinson); CyAn ADP (Cytomation); Cytek-modified 5-color BDFACScan in the MDACC-SC FACS core facility and analyzed with FlowJo software (TreeStar Inc). For confocal imaging, cells were fixed and stained with AlexaFluor647-8F4 and AlexaFluor488-BB7.2 (Serotec) as described. Prolong-Gold Antifade+Dapi (Invitrogen) was applied to the cells prior to mounting on glass slides. Imaging was performed using a Leica Microsystems SP2 SE confocal microscope at the MDACC confocal core facility with assistance from Dr. T. Zal. Cytotoxicity Assays. CDC and ADCC were performed as previously described. 22 For CDC, 2.5µg antibody and 10 6 target cells were mixed followed by the addition of 20µL of ice-cold rabbit complement (Cedarlane), which was incubated at 37ºC for 1 hour. For ADCC, PBMC from normal donors were incubated with IL-2 (200 U/mL) for 5 days to generate effectors, 11 before addition of T2 target cells +/-8F4 for 16 hours at E:T=40:1. Mouse anti-KLH IgG2a (iso, R&D Systems) and BB7.2, were used as controls in in vitro cytotoxicity experiments.
Method A (Figure 3) 
where L spontaneous and L maximum are luminescence measured before and after the addition of the cytotoxic agent digitonin, respectively.
Method B (Figure 4 ): Subset-specific cytotoxicity was measured by calculating the absolute cell numbers in treated and untreated CDC samples by flow cytometry. After CDC, cells were stained with lineage Ab cocktail (CD3, CD4, CD8, CD19, CD20, CD14, CD16), CD34, CD38, 8F4 and Live/DeadFixableAqua, washed, fixed, mixed with Caltag Counting Beads (Invitrogen) and analyzed by flow cytometry. Frequencies of gated Live/DeadFixableAqua-and Lin-CD34+CD38-events were used to calculate absolute number (N) of live and stem cells, respectively. SL% was calculated as SL%=100x(N untreated -N treated )/N untreated .
Colony-Forming Assay. Viable nucleated cells at 2×10
5 cells/mL in Iscove IMDM with 2%FBS were incubated with PBS alone, 8F4 or isotype control antibody at 2.5µg/mL for 30 minutes prior to plating in 35-mm wells with Methocult GF H4044; (StemCell Technologies) for 10-14 days. CFU-L, CFU-E, BFU-E, CFU-GM, and CFU-GEMM Colony were enumerated in triplicate cultures.
Statistical Methods. Unpaired t-test was used to compare specific lysis in AML patients and normal donors. P-value <0.05 was considered significant. Prizm software (GraphPad) was used for data analysis.
RESULTS

Immunization and antibody screening
We used two strategies to immunize Balb/c mice. In the first approach, PR1-pulsed TAPdeficient T2 cells were injected into footpads, then draining lymph nodes were collected and the B cells were used to produce hybridomas with the P3X63 mouse myeloma fusion partner. Of 1600 hybridoma-derived clones screened by ELISA and flow cytometry, none showed specific binding to PR1/HLA-A2 (data not shown). In the second approach, PR1 refolded with rHLA-A*0201 + β2-microglobulin was injected every 2 weeks (n=4 injections) with immuno-stimulating complexes (ISCOM) and incomplete Freund's adjuvant (IFA). Sera were screened by ELISA and flow cytometry for polyclonal antibody expression. Hybridomas were produced from the spleens of animals with reactivity to PR1 in sera. A total of 2850 clones from 2 mice were tested by parallel screening for binding to PR1/HLA-A2 but not to pp65/HLA-A2, an irrelevant cytomegalovirus (CMV) control peptide. 23, 24 Clones that showed at least 2-fold higher ELISA signal with PR1/HLA-A2 compared to pp65/HLA-A2 were subcloned to test single cell-derived colonies. Mice that received ISCOM yielded 10 clones that bound PR1/HLA-A2 but not pp65/HLA-A2 by ELISA. Antibody from only one clone was confirmed by flow cytometry to bind to T2 cells loaded with PR1 but not to T2 cells loaded with pp65 (not shown). This clone was designated 8F4 and was identified with isotype-specific antibodies as an IgG2a antibody subclass by ELISA (not shown)
Specificity and affinity of 8F4 binding
To confirm 8F4 specificity, we used an ELISA to show that 8F4 bound to PR1/HLA-A2 monomer ( Figure 1A-B) , but not to monomers constructed with other peptides that bind tightly to HLA-A2, such as pp65/HLA-A2 (Figure 1A) , WT1/HLA-A2, Flu/HLA-A2 25 , and HA-2/HLA-A2 26 ( Figure 1B) . In contrast, the HLA-A2-specific control antibody BB7.2 bound to all HLA-A2 monomers (SF1A). Furthermore, 8F4 did not bind PR1 peptide alone, nor to neutrophil elastase (NE) or proteinase 3 (P3), the parent proteins of PR1 ( Figure 1A) . 8F4 binding was also dependent on the concentration of PR1/HLA-A2 and of 8F4 (Figure 1A-B) . Together, the data show that 8F4 binds with specificity to PR1/HLA-A2. To determine whether 8F4 binds PR1/HLA-A2 on the cell surface, we used flow cytometry to study T2 cells loaded with PR1 or pp65.
23 8F4 showed concentrationdependent binding to PR1-pulsed T2 cells but not to pp65-pulsed cells ( Figure 1C) , whereas BB7.2 antibody bound to T2 cells loaded with either peptide (not shown), confirming 8F4 binds cell surface PR1/HLA-A2. The 8F4 antibody enabled a specific signal to be detected on T2 cells loaded with at least 1mg/mL (0.99mM) PR1. Based on the dissociation constant of PR1, we previously estimated that 1 M of PR1 correlated with 10,000 complexes per T2 cell, 23 which is similar to results obtained with a TCR-like mAb against MAGE3 peptide.
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We used surface plasmon resonance to measure 8F4-binding affinity. 8F4 bound with high affinity to soluble PR1/HLA-A2 monomer, largely due to its slow K off , with K D =9.9nM ( Figure 1D ) compared to K D =162nM for BB7.2 anti-HLA-A2 antibody (not shown). 8F4 affinity is high compared with other TCR-like mAb to peptides such as NY-ESO-1 (K D =47nM), 27 and gp100 (K D =249nM), 15 which may be an important determinant of antitumor function. Epitope mapping was investigated with two methods. First, ELISA was used to measure 8F4 binding to various peptide/HLA-A2 monomers constructed with peptides modified with alanine (Ala) substitutions at each position in PR1 ( Figure 1E ). Successful folding of the peptide/HLA-A2 monomers was verified by peptide binding to HLA-A2 19 and by recovery of purified monomer. The integrity of the peptide/HLA-A2 complex was confirmed by ELISA with BB7.2 ( Figure S1B ). Ala substitutions at P2-P9 of the PR1 reduced 8F4 binding to the peptide/HLA-A2 monomers equally compared to native PR1/HLA-A2 ( Figure 1E ). In contrast, Ala substitution at P1 resulted in significant impairment of binding to 8F4, but not to BB7.2 ( Figure S1B ). Peptide binding to HLA-A2 did not correlate with 8F4 binding to the respective monomers. For example, ALA1-PR1 bound with higher affinity to HLA-A2 (EC 50 =1.45nM) compared to PR1 (EC 50 =1.8nM) and ALA9-PR1 (EC 50 =3.11nM, data not shown). Therefore, the data suggest that P1 of PR1 contributes to optimal 8F4 binding. To study the contribution of HLA-A2 to 8F4 binding, mAbs that bound to HLA-A2 at defined epitopes were used to block 8F4 binding to PR1-and pp65-pulsed T2 cells. Binding of 8F4 to PR1-pulsed T2 cells was partially blocked by MA2.1 and BB7.2, but not by W6/32, suggesting 8F4 contacts HLA-A2 residues that are common to MA2.1 and BB7.2 recognition ( Figure 1F ). Although this could be due to simple physical hindrance, we hypothesize that a common region on HLA-A2 could connect these results and is easily tested. A common recognition region on HLA-A2 containing residues recognized by BB7.2 at position 169 and by MA2.1 at position 170, is near the terminal end of the α 2 domain. [28] [29] [30] The likelihood these are contact residues for 8F4 binding is consistent with the importance of P1 of the peptide for optimal 8F4 binding because the A pocket of HLA-A2, which accommodates P1, is bounded by aa 7, 59, 159, and an the adjacent residue at 171. 31, 32 In contrast, W6/32 binds a discontinuous epitope on the α 2 domain of HLA-A2 and β 2 m and did not block 8F4 binding, consistent with 8F4 contact residues located near the α 2 domain and the A pocket of the peptide-binding cleft. 28 The PR1 peptide analog binding and anti-HLA-A2 antibody binding data interpreted together show 8F4 binds to a combined epitope of the PR1/HLA-A2 complex.
8F4 antibody identifies high expression of PR1/HLA-A2 on myeloid leukemia
Preferential lysis of myeloid leukemia over normal hematopoietic cells by PR1-CTL correlates with the amount of intracellular P3. 23 Furthermore, T2 cells loaded with a high concentration of PR1 and leukemia cells that overexpress P3 but not normal hematopoietic cells, induce apoptosis of high avidity PR1-CTL. 33 This suggests higher PR1 expression on leukemia compared to normal hematopoietic cells. We studied this possibility with two methods. Immunofluorescent confocal imaging revealed co-localization of 8F4 and HLA-A2 on PR1-pulsed T2 cells (Figure 2A ) but not on pp65-pulsed or non-pulsed T2 cells (not shown). 8F4 and HLA-A2 also co-localized on HLA-A2 transfected U937 leukemia (not shown) that also expresses NE and P3. 34 Next, we compared PR1/HLA-A2 expression on primary AML from patients with high circulating blasts to leukocytes from healthy donors ( Table 1) . 8F4 revealed bright surface expression of PR1/HLA-A2 on blasts from AML2 but only faint expression on normal leukocytes (Figure 2A) .
In addition, PR1/HLA-A2 expression was heterogeneous on blasts from different patients and on different blasts from the same patient (Figure S2A-D) . To quantify the amount of PR1/HLA-A2 expression, we used flow cytometry to measure 8F4 fluorescence on normal hematopoietic cells and on AML blasts ( Table 1) . PR1/HLA-A2 was expressed on normal peripheral blood monocytes but not on lymphocytes or mature granulocytes ( Figure 2B ). On bone marrow cells from healthy donors, P3, NE, and PR1/HLA-A2 were co-expressed on myeloblasts ( Figures 2B & S3A-B) . 35 Low PR1/HLA-A2 expression was also observed on promyelocytes but not on maturing granulocytes, including metamyelocytes and band forms, despite high expression of P3 and NE (Figures 2B & S3) . Because proteases are mostly localized in primary granules of mature granulocytes, 36 which limits MHC-I processing, and transcription of P3 and NE is down-regulated in promyelocytes, 34, 37 it is likely that MHC-I processing of newly synthesized P3 and NE proteins also decreases during maturation, preventing PR1 expression on mature granulocytes. 38 8F4 fluorescence (MFI±SEM) was higher on blasts from five AML patients (23.7±5.18) compared to leukocytes from three healthy donors (13.6±0.23, p=0.046) and compared to blasts from an HLA-A2-patient, AML6 (4.0±2.42), as shown in Figure 2C , although there was wide variability of expression on AML cells. Although 8F4 (PR1) expression correlated with HLA-A2 expression on AML (p=0.02), there was no difference in overall HLA-A2 expression between AML and healthy donor bone marrow cells (p=0.07), suggesting that the fraction of HLA-A2 molecules bound to PR1 was higher on AML compared to normal bone marrow. Compared to T2 cells, the amount of 8F4 fluorescence suggests the number of PR1/HLA-A2 complexes on the surface of AML is < 10,000, but precise measurements were not performed. PR1/HLA-A2 expression was more heterogeneous on AML blasts compared to normal leukocytes. Surprisingly, PR1/HLA-A2 expression was similar on the Lin-CD34+CD38-stem cell-containing population from AML patients and healthy donors (p=0.8). Although PR1-CTL preferentially lyse myeloid leukemia and suppress leukemia colony formation of CML bone marrow cells but not normal hematopoietic cells, differential lysis of Lin-CD34+CD38-cells by PR1-CTL has not been directly studied. Similar PR1 expression on these cells suggests that PR1-CTL may recognize PR1 on leukemia and normal stem cells, but differences related to PR1-CTL effector function or target cell susceptibility contribute to differences in outcome. In summary, these results confirm higher expression of PR1/HLA-A2 on AML blasts compared to normal myeloblasts, monocytes, and granulocytes, although PR1 expression was similar on stem cells from AML patients and healthy donors, including cord blood cells.
8F4 induces complement-dependent cytotoxicity against AML
Because PR1-CTL induce cytolysis of leukemia, 17, 23 we sought to determine whether 8F4 similarly induced cytolysis of cells expressing PR1/HLA-A2. 8F4 induced dosedependent lysis of T2 cells pulsed with PR1, but not pp65 control peptide ( Figure 3A ) in the presence of rabbit complement, 11 demonstrating complement-dependent cytotoxicity (CDC) function of 8F4. To test the dependence of CDC on cell surface peptide concentration, we added 10µg/ml of 8F4 to T2 cells pulsed with increasing concentration of PR1 or control pp65 peptide in the presence of complement. 8F4-mediated CDC was dependent on PR1 between 1.3-10µg/mL; no lysis of pp65-pulsed T2 cells was observed ( Figure 3B ). Because total HLA-A2 expression was equivalent on T2 cells pulsed with PR1 or pp65 peptide at 1.3 to 50 µg/mL as measured with BB7.2 (not shown), these results confirm that 8F4 induces specific CDC of cells that express the PR1/HLA-A2 complex. Because PR1/HLA-A2 expression is higher on AML compared to normal hematopoietic cells, we sought to determine whether 8F4 mediated differential killing of AML versus normal leukocytes. 8F4 induced 33.51.2% and 13.91.3% CDC-mediated lysis, respectively, of PR1/HLA-A2-expressing blasts from AML1 and AML5 (Figure 3C ), but no lysis of HLA-A2-blasts from patient AML6 or HLA-A2+ PB leukocytes (> 70% neutrophils) from a healthy donor, ND4 (p<0.005). Furthermore, CDC lysis of AML was 8F4 concentration-dependent, while no CDC lysis was observed with isotype control antibody (specific for KLH) or pooled human intravenous immunoglobulin ( Figure 3D) . Therefore, 8F4 at 0.3 mg/mL, a concentration achieved with therapeutic antibodies in clinical use, 39, 40 induces CDC of PR1/HLA-A2-expressing primary AML blasts but not healthy leukocytes. We also studied whether 8F4 induced antibody-dependent cellular-cytotoxicity (ADCC), which is mediated by FcγR+ NK cells and other phagocytes. T2 cells, pulsed with PR1 or control pp65 peptide, were incubated with 8F4 or control antibody and were combined for 4-16 hours with PBMC stimulated with IL-2. 22 The observed ADCC killing was dependent on the E:T ratio, with maximum killing of 15.8±2.0%; at an E:T ratio of 40:1 ( Figure 3E) . Finally, we also looked for evidence of direct antibody-mediated cytotoxicity. In the absence of complement or effector cells, escalating doses of 8F4 did not induce cytolysis or apoptosis of U937 cells or primary AML blasts as measured by Annexin-V labeling ( Figure S4) . Therefore, 8F4 mediates modest ADCC (type II lysis), compared to CDC-mediated lysis of PR1/HLA-A2-expressing target cells.
8F4 induces CDC-mediated lysis of AML blasts and leukemia stem cells (LSC)
Leukemia is morphologically and phenotypically heterogeneous, and a cellular hierarchy can be observed that resembles normal ontogeny. 41 According to the cancer stem cell hypothesis, leukemia blasts are maintained by infrequent self-renewing LSC which are resistant to conventional therapies. 42 Consequently, effective treatment of AML must eliminate LSC to result in a cure. While there is controversy whether LSC have a unique phenotype that distinguishes them from normal hematopoietic stem cells (HSC), it has been shown that the Lin-/CD34+/CD38-population of hematopoietic cells is highly enriched for both types of stem cells. 18 Because we found similar PR1/HLA-A2 expression on both types of stem cells, we sought to determine whether 8F4 was similarly active against both Lin-/CD34+/CD38-cells. We used flow cytometry to study 8F4-induced CDC in HSC and LSC sub-populations. In this approach, microbeads were used to determine the absolute number of Lin-/CD34+/CD38-cells in samples after CDC (Figure 4A ). In the presence of complement, 8F4 induced 67% reduction of blasts from AML2, compared to 5.3% for isotype control (p<0.005). Moreover, 8F4 induced 44% CDC-mediated lysis of Lin-/CD34+/CD38-LSC compared to 23% lysis by isotype control antibody (p=0.01). This result shows that in addition to inducing cytolysis of the overall AML blast population, 8F4 also induces specific CDC-mediated lysis of LSC. To examine the potential of 8F4 as an antileukemia agent, we compared CDC effects of 8F4 against total cells, LSC, and HSC from HLA-A2+ AML patients ( Table 1) , healthy donors, cord blood cells, and HLA-A2-transfected U937 cells which express PR1, P3, and NE. 34 The amount of lysis was determined by comparing the absolute number of treated total cells or stem cells to the number of untreated cells. To calculate 8F4 specific lysis, non-specific lysis of isotypetreated cells was subtracted. As shown in Figure 4B , 8F4 induced CDC-mediated specific lysis of blasts from seven AML patients but not bone marrow cells from six healthy donors (61.2±10.0% versus 8.54.5%, p=0.0007), which is consistent with results from the luminescence-based CDC assay in Figure 3 . Furthermore, 8F4-induced CDC against AML blasts correlated directly with PR1/HLA-A2 surface expression (R 2 =0.76, p=0.05) determined by 8F4 MFI in Figure 2C . Low level CDC (<20%) of both HLA-A2-positive and HLA-A2-negative BM and PB cells from healthy donors and of HLA-A2-positive CB cells was observed with the bead-based flow cytometric assay, which showed little variation, suggestive of background lysis reflecting increased sensitivity of the assay. We next compared the effect of 8F4 on Lin-CD34+CD38-stem cells ( Figure 4C ). 8F4 induced more CDC in LSC from AML patients (n=7; 59.5±11.4%), compared to HSC from healthy bone marrow (n=6; 41.0±13.7%; p=0.09). 8F4 induced only background CDC (≤20%) against blasts and LSC from patient AML8, indicating not all HLA-A2+ AML are sensitive to 8F4. The modest difference of 8F4 mediated CDC of LSC over HSC, compared to CDC of AML blasts over normal bone marrow cells, may be due to overlapping PR1 surface expression on LSC and HSC ( Figure 2C ) and heterogeneous PR1 expression on HSC. However, the high background and high variability of the lysis measurements of HSC in particular, likely due to the lower frequency of HSC compared to LSC in each sample may obscure true differences of 8F4 lysis. While HLA-A2 expression was 2-fold higher on HSC compared to LSC (MFI of 3537 vs 1834, p=0.02), there was no difference in overall PR1 expression (MFI of 464 vs 335, p=0.8). This is consistent with a higher fractional occupancy of HLA-A2 molecules by PR1 on LSC, which may increase the efficiency of CDC lysis on LSC because higher ligand density amplifies complement activation by Ab cross-linking. 43, 44 Nevertheless, a more accurate determination of potential differences in activity may require a more precise method and increased sample sizes.
8F4 inhibits leukemia progenitor cells but not normal progenitor cell growth
Because 8F4 shows lytic potential against LSC and HSC, we looked for differential activity against leukemia and normal progenitor cells with a more established assay. We measured colony-forming units (CFU) of granulocyte-macrophages (CFU-GM), granulocyte-erythroid-myeloid-megakaryocyte (CFU-GEMM), erythrocytes (CFU-E), and erythrocyte blast-forming units (BFU-E) from healthy donor BM and CB, and leukemiaforming units (LFU) from AML patients that were treated with 8F4 or control antibody prior to plating in semi-solid agar. Colonies per 10 5 mononuclear cells were counted 10-14 days later. 8F4 significantly inhibited leukemia progenitors from patients AML1 (p=0.04), AML7 (p=0.03), and AML9 (p=0.008) (Figure 5A ), but not progenitors from patient ALL1, which lacked expression of P3, NE, and PR1 (not shown). There was no statistically significant effect of 8F4 against ALL1 despite low colony numbers. In contrast, 8F4 showed no inhibitory activity against progenitor cells from cord blood units, or from normal BM (Figure 5B-C) . In the presence of complement, 8F4 inhibited LFU from patient AML1 by 65%, compared to 20% to 33% inhibition of normal progenitor cells (BFU-E and CFU-GEMM, respectively) from 5 healthy donors (p<0.0001) ( Figure  5D ). These results show that 8F4 preferentially inhibits leukemia progenitors over normal hematopoietic progenitors despite similar surface expression of PR1/HLA-A2 on Lin-/CD34+/CD38-progenitor cells. Furthermore, the leukemia-specific activity of 8F4 in the presence and absence of complement suggests an alternative mechanism of growth inhibition in addition to CDC.
DISCUSSION
We report the discovery of 8F4, a novel TCR-like IgG2a, which is the first mAb against an endogenous leukemia-associated antigen overexpressed on the cell surface of myeloid leukemia. We showed that 8F4 binds with high affinity (K D =9.9nM) to a conformational epitope of PR1/HLA-A2, with contact residues near P1 of the PR1 peptide and the N-terminus of the α 2 helical domain of HLA-A2. From confocal microscopy and flow cytometry experiments, PR1/HLA-A2 expression was high but heterogeneous on AML blasts compared to normal leukocytes, and low expression was observed on Lin-CD34+CD38-LSC. Interestingly, low PR1/HLA-A2 expression was seen on HSC and early myeloid progenitors including myeloblasts and promyelocytes, but not differentiated myeloid cells or mature granulocytes. Although 8F4 showed weak ADCC, 8F4 mediated dose-dependent CDC against AML blasts that correlated with PR1/HLA-A2 expression and CDC against LSC, but not against normal leukocytes from bone marrow or cord blood. Importantly, although 8F4 mediated modest CDC against normal HSC, colony-forming assays showed 8F4 preferentially inhibited leukemia progenitor cells but not normal hematopoietic progenitor cells, despite similar PR1/HLA-A2 expression on LSC and HSC. TCR-like mAbs have been produced against a range of tumor antigens, including HLA-A2-and A1-restricted peptides derived from NY-ESO-1, 13 β-HCG, 11 and MART-1.
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TCR-like mAb show mostly CDC activity, although ADCC and direct type II cytotoxic apoptosis induction have been observed. 11 However, most studies with unconjugated TCR-like mAbs show activity against tumor cell lines and against cell line-derived tumors in xenogeneic mouse models rather than against primary tumors.
11,16 These and similar antibodies have been used to study MHC antigen presentation, to localize and quantify antigen-presenting cells (APC) displaying a T cell epitope, to specifically mask an autoimmune T cell epitope, and as a tool to induce lysis of epitope-expressing solid tumor cell lines in vitro and in vivo models. TCR-like mAbs have been produced from conventional hybridoma approaches and from phage display libraries. Those mAbs selected from Fab or scFv antibody phage display libraries have relatively low affinities (50-250nM), 14, 15, 27 and may potentially cross-react with other peptide/MHC complexes. In contrast, 8F4 was generated by direct immunization and as a result has a high affinity for PR1/HLA-A2 (K D =10nM), similar to the binding affinity reported for Fab T1 (K D =2-4nM), a TCR-like mAb that was selected by affinity maturation from a peptide-focused 2 nd generation Fab library 27 and is considered to have high binding affinity. While our study was not an exhaustive search for multiple epitope-specific antibodies, 78% of colonies recognized HLA-A2 after immunization and only a single anti-PR1/HLA-A2 antibody was isolated, which may reflect that only one such specificity exists or that other specificities were not generated during the murine immune response. Alternatively, weakly binding clones could be lost during the selection procedure, resulting in the isolation of a single, strongly binding clone. TCR-like mAbs produced by xenogeneic immunization have also resulted in mAbs with potential cross-reactivity to other selfpeptides. Therefore, while there was no evidence of cross reactivity in our study, additional studies ought to explore potential cross-reactivity of 8F4. More patients must be studied to understand the range of PR1/HLA-A2 expression and the relationship of AML CML, MDS (and LSCs) to 8F4-mediated lysis. This study also suggests that TCRlike antibodies might be developed against other leukemia-associated and leukemiaspecific peptide/HLA complexes to broaden the therapeutic potential of this approach. Interestingly, 8F4-mediated CDC of leukemia blasts correlated with PR1/HLA-A2 expression, but CDC of LSC was only modestly higher than CDC of normal HSC and did not correlate with PR1/HLA-A2 expression. There are many potential reasons why we did not observe a greater effect on LSC versus HSC. Due to the low frequency of LSC and HSC in all of the patient and donor samples, measurement errors of CDC lysis are amplified due to the low event rate. This reduces the precision of each measurement and decreases the ability to discern statistical differences in the LSC and HSC groups. This is supported by the larger SEM in lysis measurements on stem cells ( Figure 4C ) compared to the corresponding SEM of measurements on the more frequent blast and normal leukocyte populations ( Figure 4B ). Second, because PR1 expression was low on all stem cell populations, potential cross-reactivity of 8F4 may result in some lysis of HSC. Third, CDC is unlikely to be the only mechanism of 8F4 activity, as suggested by the preferential inhibition of leukemia progenitors by 8F4 in the absence of complement ( Figure 5 ). For instance, 8F4 may induce direct effects on cell growth or survival 44, 45 and potentially significant differences of 8F4-induced apoptosis of LSC and HSC might not be evident because of the high non-specific apoptosis of control-treated cells ( Figure  S4A-B) . Fourth, the observed difference of CDC on LSC and HSC, while not statistically significant (p = 0.07), might still be biologically significant. For example, while the overall expression of PR1/HLA-A2 was similar on LSC as well as normal myeloblasts, promyelocytes, and HSC, a higher surface density of PR1/HLA-A2 complexes on LSC would support more lysis because of amplified complement activation from Ab crosslinking. 43 In addition, myeloid malignancies may be more susceptible to CDC because of variable expression of CD55 and CD59, [46] [47] [48] which are critical proteins for preventing complement activation. Specific lysis of myeloid leukemia by PR1-CTL and specific inhibition of CML progenitor cells in standard colony forming assays correlates with aberrant expression of P3 in target cells. 17, 23 However, high PR1 surface expression, likely the result of high intracellular P3, induces selective apoptosis of PR1-CTL with high avidity TCR, which are more potent effector cells compared to low avidity PR1-CTL, which are not killed by high PR1-expressing target cells. 33 This implies that the relative high PR1 surface expression on leukemia causes deletion of PR1-CTL, which permits leukemia outgrowth. Conversely, a narrow range of low PR1 surface expression on HSC and immature myeloid cells may function normally to permit the small number of PR1-CTL to be maintained during T cell homeostasis. 49, 50 Moreover, because low PR1 expression is similar on normal HSC and LSC, we speculate this would allow LSC, like HSC under physiological conditions, to escape immune recognition by low avidity PR1-CTL because PR1 expression is insufficient to reach activation threshold. While high avidity PR1-CTL are more likely to recognize LSC, they are much less frequent (1/800,000 CD8+ cells) 19, 33 and are therefore less likely to encounter low frequency LSC. In contrast, the higher PR1 expression on leukemia blasts compared to LSC might be sufficient to cause recognition by low avidity PR1-CTL, although low avidity PR1-CTL are less effective killers. 8F4 will be helpful to study the role of PR1 expression on differential recognition of LSC, blasts, and HSC by high and low avidity PR1-CTL. Because 8F4 induced lysis of AML blasts and LSC and inhibited leukemia progenitor cell growth, anti-PR1/HLA-A2 antibodies may have therapeutic potential. Because PR1 expression is similar on LSC and HSC, it will be important to further define potential ontarget toxicity against HSC, which could be studied in a xenogeneic mouse model. Nevertheless, because AML is often a fatal disease and 8F4 is highly active against blasts and LSC, which are ordinarily resistant to cytotoxic agents, further study of 8F4 is justified. 
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The authors have no conflict of interest to declare. by 33% compared to isotype control (p=0.004). Similarly, 8F4 inhibits day 10 CFU-L from AML7 (AML-M7) by 44% (p=0.03), AML9 (AML-M1) 41% (p=0.008), respectively. 8F4 does not inhibit CFU-L from patient ALL1. (B) 8F4 has no effect on CFU-E, BFU-E, CFU-GM and CFU-GEMM from HLA-A2+ umbilical cord blood (CB) units. Day 14 CFU-E count is not significantly different between 8F4-and isotype-treated mononuclear cells, similar results from BFU-E, CFU-GM and CFU-GEMM. Representative experiment out of three performed with independent CB units shown. (C) 8F4 has no effect on CFU-E, BFU-E, CFU-GM and CFU-GEMM from fresh HLA-A2+ normal bone marrow. Day 14 CFU-E count is not significantly different between 8F4-and isotype-treated mononuclear cells, similar results from BFU-E, CFU-GM and CFU-GEMM. 
